Masuda N - Search Results

1

Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. Rugo HS, et al. Among authors: masuda n. Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25. Eur J Cancer. 2018. PMID: 30053671

2

Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.

Masuda N, Nakayama T, Yamamura J, Kamigaki S, Taguchi T, Hatta M, Sakamoto J. Masuda N, et al. Cancer Chemother Pharmacol. 2010 May;66(1):89-94. doi: 10.1007/s00280-009-1137-z. Epub 2009 Sep 19. Cancer Chemother Pharmacol. 2010. PMID: 19768460 Clinical Trial.

3

Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.

Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Toi M, et al. Among authors: masuda n. Cancer. 2010 Jul 1;116(13):3112-8. doi: 10.1002/cncr.25206. Cancer. 2010. PMID: 20564629 Free article.

4

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S. Masuda N, et al. Lancet Oncol. 2012 Apr;13(4):345-52. doi: 10.1016/S1470-2045(11)70373-4. Epub 2012 Jan 20. Lancet Oncol. 2012. PMID: 22265697 Clinical Trial.

5

Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.

Iwata H, Masuda N, Sagara Y, Kinoshita T, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Tsuda H, Hayashi N, Noguchi S. Iwata H, et al. Among authors: masuda n. Cancer. 2013 Feb 15;119(4):704-13. doi: 10.1002/cncr.27818. Epub 2012 Sep 12. Cancer. 2013. PMID: 22972694 Free article. Clinical Trial.

6

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y. Noguchi S, et al. Among authors: masuda n. Breast Cancer. 2014 Nov;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13. Breast Cancer. 2014. PMID: 23404211 Free PMC article. Clinical Trial.

7

Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.

Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Beck JT, et al. Among authors: masuda n. Breast Cancer Res Treat. 2014 Feb;143(3):459-67. doi: 10.1007/s10549-013-2814-5. Epub 2013 Dec 21. Breast Cancer Res Treat. 2014. PMID: 24362951 Free PMC article. Clinical Trial.

8

The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.

Kim SJ, Masuda N, Tsukamoto F, Inaji H, Akiyama F, Sonoo H, Kurebayashi J, Yoshidome K, Tsujimoto M, Takei H, Masuda S, Nakamura S, Noguchi S. Kim SJ, et al. Among authors: masuda n, masuda s. Cancer Lett. 2014 Dec 28;355(2):217-23. doi: 10.1016/j.canlet.2014.08.042. Epub 2014 Sep 10. Cancer Lett. 2014. PMID: 25218592

9

[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].

Enami A, Masuda N, Yamamura J, Mizutani M, Yasojima H, Shikata A, Masaoka M, Takada S, Bamba N, Yamamoto M, Abe M, Makihara K. Enami A, et al. Among authors: masuda n. Gan To Kagaku Ryoho. 2014 Nov;41(11):1407-12. Gan To Kagaku Ryoho. 2014. PMID: 25434444 Japanese.

10

[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

Ito Y, Masuda N, Iwata H, Mukai H, Horiguchi J, Tokuda Y, Kuroi K, Mori A, Ohno N, Noguchi S. Ito Y, et al. Among authors: masuda n. Gan To Kagaku Ryoho. 2015 Jan;42(1):67-75. Gan To Kagaku Ryoho. 2015. PMID: 25596682 Clinical Trial. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,199 results

Search Page

Filters